SM Silverstein, MG Cable, E Sadri… - Current Medical …, 2011 - informahealthcare.com A total of 455 subjects (455 study eyes: 230 bromfenac, 225 placebo) were enrolled in two randomized double-masked, placebo-controlled, clinical trials at 64 ophthalmology clinics in the United States. Subjects were randomized to receive either bromfenac 0.09% or placebo dosed ...
R Nathawad, H Mendez, A Ahmad… - The Pediatric …, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > Current ... Related articles - All 5 versions
HA KETELSON… - WO Patent WO/2011/068,955, 2011 - wipo.int The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. ... 1. (WO2011068955) OPHTHALMIC EMULSION. Pub. ... Cached
J Chui, MT Coroneo, LT Tat, R Crouch… - The American Journal of …, 2011 - Elsevier Pterygia are common ocular surface lesions thought to originate from limbal stem cells altered by chronic UV exposure. Traditionally regarded as a degenerative condition, pterygia also display tumor-like features, such as a propensity to invade normal tissue and high recurrence ... Cited by 1 - Related articles - All 4 versions
, … , for the Bepotastine Besilate Ophthalmic … - Journal of Ocular …, 2011 - liebertonline.com To cite this article: Jon I. Williams, Kathryn S. Kennedy, James A. Gow, Gail L. Torkildsen, Mark B. Abelson, Paul J. Gomes, Timothy R. McNamara, for the Bepotastine Besilate Ophthalmic Solutions Study Group. Journal of Ocular Pharmacology and Therapeutics. -Not available-, ahead ... Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
